Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Onsenal opvejer risiciene i forbindelse med reduktion af antallet af adenomatøse tarmpolypper ved FAP, når Onsenal bruges som tillæg til kirurgisk indgreb og anden endoskopisk overvågning.
The Committee for Medicinal Products for Human Use (CHMP) decided that Onsenal’ s benefits are greater than its risks for the reduction of the number of adenomatous intestinal polyps in FAP as an adjunct to surgery and further endoscopic surveillance.